Abstract
* The FDA is restricting access to rosiglitazone, used in the treatment of type 2 diabetes, until reassessment of its cardiovascular risk is completed.
* Patients shouldn't be started on rosiglitazone unless medically necessary; those already taking it have the option to continue.
* Everyone prescribing, taking, or dispensing the drug must be enrolled in the restricted-access program.